Marksans Pharma Limited has announced that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets in the UK. The product will be marketed as Bell’s Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets.
In the exchange filing, the company shared, “Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell’s Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).”
This approval strengthens Marksans Pharma’s presence in the UK market, expanding its portfolio of over-the-counter (OTC) pain relief medications. The combination of ibuprofen and paracetamol offers effective dual-action pain relief, making it a valuable addition to the company’s pain management solutions.
